Overview

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well bendamustine hydrochloride, obinutuzumab, and dexamethasone work in treating older patients with diffuse large B-cell lymphoma. Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as obinutuzumab, may find cancer cells and help kill them. Giving bendamustine hydrochloride, obinutuzumab, and dexamethasone may kill more cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborator:
National Cancer Institute (NCI)
Treatments:
BB 1101
Bendamustine Hydrochloride
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Obinutuzumab
Rituximab